Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of multiparametric MR with neurovascular bundle evaluation to optimize the oncological and functional management of patients considered for nerve-sparing radical prostatectomy.
Panebianco V, Salciccia S, Cattarino S, Minisola F, Gentilucci A, Alfarone A, Ricciuti GP, Marcantonio A, Lisi D, Gentile V, Passariello R, Sciarra A. Panebianco V, et al. Among authors: lisi d. J Sex Med. 2012 Aug;9(8):2157-66. doi: 10.1111/j.1743-6109.2012.02794.x. Epub 2012 May 29. J Sex Med. 2012. PMID: 22642466 Clinical Trial.
Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy.
Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Gentilucci A, Lisi D, Passariello R, Gentile V, Di Silverio F. Sciarra A, et al. Among authors: lisi d. Eur Urol. 2008 Mar;53(3):652-5. doi: 10.1016/j.eururo.2007.02.010. Epub 2007 Feb 15. Eur Urol. 2008. PMID: 17316966
Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer.
Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Di Silverio F, Gentile V. Sciarra A, et al. Among authors: lisi d. Eur Urol. 2008 Sep;54(3):589-600. doi: 10.1016/j.eururo.2007.12.034. Epub 2007 Dec 31. Eur Urol. 2008. PMID: 18226441
2D and 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy with erectile function correlation.
Panebianco V, Sciarra A, Osimani M, Lisi D, Ciccariello M, Salciccia S, Gentile V, Di Silverio F, Passariello R. Panebianco V, et al. Among authors: lisi d. Eur Radiol. 2009 Jan;19(1):220-9. doi: 10.1007/s00330-008-1102-y. Epub 2008 Jul 24. Eur Radiol. 2009. PMID: 18651150 Clinical Trial.
Use of 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy (RRP): a potential diagnostic tool for optimal management of erectile dysfunction after RRP.
Sciarra A, Panebianco V, Salciccia S, Alfarone A, Gentilucci A, Lisi D, Passariello R, Gentile V. Sciarra A, et al. Among authors: lisi d. J Sex Med. 2009 May;6(5):1430-7. doi: 10.1111/j.1743-6109.2009.01241.x. J Sex Med. 2009. PMID: 19473289
Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Bernardo S, Passariello R, Gentile V. Sciarra A, et al. Among authors: lisi d. Clin Cancer Res. 2010 Mar 15;16(6):1875-83. doi: 10.1158/1078-0432.CCR-09-2195. Epub 2010 Mar 2. Clin Cancer Res. 2010. PMID: 20197480 Clinical Trial.
Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, Gentile V, Laghi A, Passariello R. Panebianco V, et al. Among authors: lisi d. Eur J Radiol. 2012 Apr;81(4):700-8. doi: 10.1016/j.ejrad.2011.01.095. Epub 2011 Feb 17. Eur J Radiol. 2012. PMID: 21330082 Clinical Trial.
Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR).
Sciarra A, Panebianco V, Salciccia S, Lisi D, Alfarone A, Gentilucci A, Parente U, Cattarino S, Passariello R, Gentile V. Sciarra A, et al. Among authors: lisi d. Urol Oncol. 2012 Sep;30(5):614-9. doi: 10.1016/j.urolonc.2010.09.006. Epub 2011 Mar 10. Urol Oncol. 2012. PMID: 21396849 Clinical Trial.
186 results